Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Jun;33(6):895–905. doi: 10.1128/aac.33.6.895

Selection of orally active antifungal agents from 3,5-substituted isoxazolidine derivatives based on acute efficacy-safety profiles.

G C Palmer 1, M J Ordy 1, R D Simmons 1, J C Strand 1, L A Radov 1, G B Mullen 1, C R Kinsolving 1, V St Georgiev 1, J T Mitchell 1, S D Allen 1
PMCID: PMC284252  PMID: 2764540

Abstract

Routine in vitro screening of a new synthetic series of 3,5-substituted 2-methylisoxazolidines revealed that three imidazole analogs (PR 967-248, PR 967-234, and PR 969-566) and, to a lesser extent, a triazole analog (PR 988-399) exerted rather potent antifungal activity against three systemic and four dermatophytic classes of fungi. When tested in vivo for ability to eradicate Candida vaginitis in the rat, the triazole derivative, PR 988-399, was effective after oral administration. In this in vivo test for efficacy, PR 967-234 and PR 969-566 reduced but did not eradicate the infection, while PR 967-248 was inactive. PR 988-399 was, moreover, 4- to 13-fold less potent than the three imidazoles in inhibiting testosterone synthesis in isolated rat Leydig cells. After oral or intravenous administration, PR 988-399 and PR 969-566 elicited the fewest cardiovascular and behavioural side effects in conscious dogs. The rat safety study consisted of oral dosing followed by evaluation of the exploratory motor activity of the naive animals in a novel environment. Motor activity was suppressed least by PR 988-399 and most by PR 969-566. In a battery of mouse behavioural-neuromuscular-drug interaction tests, PR 988-399 and PR 969-566 produced the fewest central-behavioural-neuromuscular signs. These efficacy-safety evaluations were performed with ketoconazole as a positive reference standard. The sequence of drug testing with respect to efficacy-safety considerations appears to be a suitable approach for early detection of orally active antifungal agents such as PR 988-399 for more advanced development.

Full text

PDF
895

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Artru A. A., Michenfelder J. D. Influence of hypothermia or hyperthermia alone or in combination with pentobarbital or phenytoin on survival time in hypoxic mice. Anesth Analg. 1981 Dec;60(12):867–870. [PubMed] [Google Scholar]
  2. Borelli D., Bran J. L., Fuentes J., Legendre R., Leiderman E., Levine H. B., Restrepo A., Stevens D. A. Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J. 1979 Sep;55(647):657–661. doi: 10.1136/pgmj.55.647.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Campbell E. S., Richter W. An observational method estimating toxicity and drug actions in mice applied to 68 reference drugs. Acta Pharmacol Toxicol (Copenh) 1967;25(3):345–363. doi: 10.1111/j.1600-0773.1967.tb01443.x. [DOI] [PubMed] [Google Scholar]
  4. Coughenour L. L., Mclean J. R., Parker R. B. A new device for the rapid measurement of impaired motor function in mice. Pharmacol Biochem Behav. 1977 Mar;6(3):351–353. doi: 10.1016/0091-3057(77)90036-3. [DOI] [PubMed] [Google Scholar]
  5. Coward D. M., Doggett N. S., Sayers A. C. The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent. Arzneimittelforschung. 1977;27(12):2326–2332. [PubMed] [Google Scholar]
  6. DeCory T. R., Swift P. A., Mullen G. B., Mitchell J. T., Allen S. D., Kinsolving C. R., St Georgiev V. cis-3-(substituted phenyl)-3-(1H-imidazol-1-ylmethyl)-2-methyl-5-([(substituted phenyl)thio(or amino)]methyl)isoxazolidines. In vitro antifungal activity and structure-activity relationships. Ann N Y Acad Sci. 1988;544:366–368. doi: 10.1111/j.1749-6632.1988.tb40424.x. [DOI] [PubMed] [Google Scholar]
  7. DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. doi: 10.1152/ajpendo.1978.235.2.E97. [DOI] [PubMed] [Google Scholar]
  8. Dean R. L., 3rd, Scozzafava J., Goas J. A., Regan B., Beer B., Bartus R. T. Age-related differences in behavior across the life span of the C57BL/6J mouse. Exp Aging Res. 1981 Winter;7(4):427–451. doi: 10.1080/03610738108259823. [DOI] [PubMed] [Google Scholar]
  9. Drouhet E., Dupont B. Evolution of antifungal agents: past, present, and future. Rev Infect Dis. 1987 Jan-Feb;9 (Suppl 1):S4–14. doi: 10.1093/clinids/9.supplement_1.s4. [DOI] [PubMed] [Google Scholar]
  10. Graybill J. R., Craven P. C. Antifungal agents used in systemic mycoses. Activity and therapeutic use. Drugs. 1983 Jan;25(1):41–62. doi: 10.2165/00003495-198325010-00003. [DOI] [PubMed] [Google Scholar]
  11. Heeres J., Backx L. J., Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem. 1984 Jul;27(7):894–900. doi: 10.1021/jm00373a015. [DOI] [PubMed] [Google Scholar]
  12. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968 Sep 20;13(3):222–257. doi: 10.1007/BF00401402. [DOI] [PubMed] [Google Scholar]
  13. LESLIE G. B., MAXWELL D. R. INHIBITION OF TREMORINE BY A GROUP OF NON-ANTI-PARKINSON PHENOTHIAZINE DERIVATIVES. Nature. 1964 Apr 4;202:97–98. doi: 10.1038/202097a0. [DOI] [PubMed] [Google Scholar]
  14. Medoff G., Brajtburg J., Kobayashi G. S., Bolard J. Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol. 1983;23:303–330. doi: 10.1146/annurev.pa.23.040183.001511. [DOI] [PubMed] [Google Scholar]
  15. Meunier-Carpentier F., Kiehn T. E., Armstrong D. Fungemia in the immunocompromised host. Changing patterns, antigenemia, high mortality. Am J Med. 1981 Sep;71(3):363–370. doi: 10.1016/0002-9343(81)90162-5. [DOI] [PubMed] [Google Scholar]
  16. Moyle W. R., Ramachandran J. Effect of LH on steroidogenesis and cyclic AMP accumulation in rat Leydig cell preparations and mouse tumor Leydig cells. Endocrinology. 1973 Jul;93(1):127–134. doi: 10.1210/endo-93-1-127. [DOI] [PubMed] [Google Scholar]
  17. Mullen G. B., DeCory T. R., Mitchell J. T., Allen S. D., Kinsolving C. R., Georgiev V. S. Studies on antifungal agents. 23. Novel substituted 3,5-diphenyl-3-(1H-imidazol-1-ylmethyl)- 2-alkylisoxazolidine derivatives. J Med Chem. 1988 Oct;31(10):2008–2014. doi: 10.1021/jm00118a027. [DOI] [PubMed] [Google Scholar]
  18. Nakamura J., Yamada K., Shuto K., Marumo H. [General pharmacological studies on cis-1-acetyl-4-[4-[[2-(2, 4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy] phenyl] piperazine]. Jpn J Antibiot. 1982 Jun;35(6):1629–1648. [PubMed] [Google Scholar]
  19. OKUN R., LIDDON S. C., LASAGNA L. The effects of aggregation, electric shock, and adrenergic blocking drugs on inhibition of the "writhing syndrome". J Pharmacol Exp Ther. 1963 Jan;139:107–109. [PubMed] [Google Scholar]
  20. Odds F. C., Milne L. J., Gentles J. C., Ball E. H. The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. J Antimicrob Chemother. 1980 Jan;6(1):97–104. doi: 10.1093/jac/6.1.97. [DOI] [PubMed] [Google Scholar]
  21. Pont A., Williams P. L., Azhar S., Reitz R. E., Bochra C., Smith E. R., Stevens D. A. Ketoconazole blocks testosterone synthesis. Arch Intern Med. 1982 Nov;142(12):2137–2140. [PubMed] [Google Scholar]
  22. Porter R. J., Cereghino J. J., Gladding G. D., Hessie B. J., Kupferberg H. J., Scoville B., White B. G. Antiepileptic Drug Development Program. Cleve Clin Q. 1984 Summer;51(2):293–305. doi: 10.3949/ccjm.51.2.293. [DOI] [PubMed] [Google Scholar]
  23. Rippon J. W. A new era in antimycotic agents. Arch Dermatol. 1986 Apr;122(4):399–402. [PubMed] [Google Scholar]
  24. Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986 Sep;30(3):418–422. doi: 10.1128/aac.30.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Saag M. S., Dismukes W. E. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother. 1988 Jan;32(1):1–8. doi: 10.1128/aac.32.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Sobel J. D., Muller G. Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother. 1984 Feb;25(2):281–282. doi: 10.1128/aac.25.2.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sonino N. The use of ketoconazole as an inhibitor of steroid production. N Engl J Med. 1987 Sep 24;317(13):812–818. doi: 10.1056/NEJM198709243171307. [DOI] [PubMed] [Google Scholar]
  28. Van Tyle J. H. Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984 Nov-Dec;4(6):343–373. doi: 10.1002/j.1875-9114.1984.tb03398.x. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES